Hypericum Extract Reverses S-Ketamine-Induced Changes in Auditory Evoked Potentials in Humans – Possible Implications for the Treatment of Schizophrenia

[1]  M. Uhr,et al.  Effects of Hypericum Extract (LI160) on the Change of Auditory Evoked Potentials by Cortisol Administration , 2004, Neuropsychobiology.

[2]  B. Turetsky,et al.  Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential , 2004, Neuropsychopharmacology.

[3]  D. Lara,et al.  Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia , 2004, Clinical Neurophysiology.

[4]  Bob Oranje,et al.  Modulating sensory gating in healthy volunteers The effects of ketamine and haloperidol , 2002, Biological Psychiatry.

[5]  J. Davies,et al.  The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. , 2002, Life sciences.

[6]  L. Cervo,et al.  Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts , 2002, Psychopharmacology.

[7]  Brett A. Clementz,et al.  Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia , 2001, Experimental Brain Research.

[8]  Erica Duncan,et al.  Clinical and Sensorimotor Gating Effects of Ketamine in Normals , 2001, Neuropsychopharmacology.

[9]  T. Dinan,et al.  Glucocorticoids and cognitive function: from physiology to pathophysiology , 2001, Human psychopharmacology.

[10]  J. Greeson,et al.  St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature , 2001, Psychopharmacology.

[11]  E. Walker,et al.  Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia , 2000, Biological Psychiatry.

[12]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[13]  C. Gonsalvez,et al.  Misattribution of sensory input reflected in dysfunctional target[ratio ]non-target ERPs in schizophrenia , 2000, Psychological Medicine.

[14]  R. Tandon,et al.  Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome , 2000, Schizophrenia Research.

[15]  R. Sapolsky,et al.  Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. , 2000, Archives of general psychiatry.

[16]  P. Singh,et al.  Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. , 2000, Journal of ethnopharmacology.

[17]  W. Müller,et al.  Inhibition of Synaptosomal Uptake of 3H-L-glutamate and 3H-GABA by Hyperforin, a Major Constituent of St. John's Wort: The Role of Amiloride Sensitive Sodium Conductive Pathways , 2000, Neuropsychopharmacology.

[18]  D L Braff,et al.  Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. , 2000, The American journal of psychiatry.

[19]  C. Schroeder,et al.  Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP) , 2000, Clinical Neurophysiology.

[20]  J. Daléry,et al.  Alteration of event related potentials in siblings discordant for schizophrenia , 2000, Schizophrenia Research.

[21]  A. Belger,et al.  Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions , 2000, Biological Psychiatry.

[22]  A. Altamura,et al.  HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment , 1999, European Neuropsychopharmacology.

[23]  A. Carlsson,et al.  Neurotransmitter interactions in schizophrenia—therapeutic implications , 1999, Biological Psychiatry.

[24]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[25]  M. Marie-cardine,et al.  Auditory event-related potentials and clinical scores in unmedicated schizophrenic patients , 1999, Psychiatry Research.

[26]  D. Javitt,et al.  Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction , 1999, Schizophrenia Research.

[27]  F. Holsboer,et al.  The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. , 1999, Journal of psychiatric research.

[28]  L. Carlson,et al.  Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women , 1999, Neurobiology of Aging.

[29]  S. Kaehler,et al.  Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus , 1999, Neuroscience Letters.

[30]  J. Pepping.  St. John's wort: Hypericum perforatum. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[31]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[32]  R. Kahn,et al.  The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects , 1998, Psychopharmacology.

[33]  H. Lehfeld,et al.  The SKT—A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention , 1997, International Psychogeriatrics.

[34]  A. Nahrstedt,et al.  Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. , 1997, Pharmacopsychiatry.

[35]  P. Tueting,et al.  Auditory evoked potentials, clinical vs. research applications , 1997, Psychiatry Research.

[36]  R. M. Murray,et al.  The Maudsley Family Study, II: Endogenous event-related potentials in familial schizophrenia , 1997, Schizophrenia Research.

[37]  J. Ford,et al.  ERPs in schizophrenia: Effects of antipsychotic medication , 1994, Biological Psychiatry.

[38]  M. Martinelli,et al.  Influences of dimethindene maleate in a new formulation on oculo and psychomotor performance using the oculodynamic test (ODT) in volunteers , 1994, Agents and Actions.

[39]  R. Freedman,et al.  Defects in auditory sensory gating and their apparent compensation in relatives of schizophrenics , 1988, Schizophrenia Research.

[40]  A Pfefferbaum,et al.  Event-related potentials in schizophrenics. , 1980, Electroencephalography and clinical neurophysiology.

[41]  M. Mannel.  Drug Interactions with St John’s Wort , 2001, Canadian family physician Medecin de famille canadien.

[42]  F. Duffy,et al.  Clinical correlations of auditory P200 topography and left temporo-central deficits in schizophrenia: a preliminary study. , 1989, Journal of psychiatric research.